We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$88M
Cap. Flow
+$2.36M
Cap. Flow %
0.12%
Top 10 Hldgs %
47.92%
Holding
151
New
44
Increased
37
Reduced
36
Closed
31

Top Buys

Rank Stock Value
1
BKD icon
Brookdale Senior Living
BKD
+$44.7M
2
WELL icon
Welltower
WELL
+$35.8M
3
DOC icon
Healthpeak Properties
DOC
+$33.9M
4
ABVX
Abivax
ABVX
+$32.7M
5
OHI icon
Omega Healthcare
OHI
+$26.7M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$48.5M
2
DHR icon
Danaher
DHR
+$42.6M
3
VERA icon
Vera Therapeutics
VERA
+$38.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$31.7M
5
BRKR icon
Bruker
BRKR
+$27.9M

Sector Composition

Rank Sector Weight
1 Healthcare 74.35%
2 Real Estate 5.59%
3 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
126
DELISTED
Cidara Therapeutics
CDTX
– –
-98,721
Closed -$21.8M
CGON icon
127
CG Oncology
CGON
$6.11B
– –
-308,466
Closed -$12.8M
CPRX
128
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-358,168
Closed -$8.36M
CVS icon
129
CVS Health
CVS
$137B
– –
-63,696
Closed -$5.05M
DHR icon
130
Danaher
DHR
$135B
– –
-186,262
Closed -$42.6M
DVAX
131
DELISTED
Dynavax Technologies
DVAX
– –
-605,976
Closed -$9.32M
ELV icon
132
Elevance Health
ELV
$81.9B
– –
-30,195
Closed -$10.6M
EOLS icon
133
Evolus
EOLS
$394M
– –
-344,104
Closed -$2.29M
EWTX icon
134
Edgewise Therapeutics
EWTX
$4.39B
– –
-337,340
Closed -$8.37M
EXAS
135
DELISTED
Exact Sciences
EXAS
– –
-241,678
Closed -$24.5M
FTRE icon
136
Fortrea Holdings
FTRE
$1.85B
– –
-224,139
Closed -$3.87M
HUM icon
137
Humana
HUM
$46.7B
– –
-32,462
Closed -$8.31M
ILMN icon
138
Illumina
ILMN
$29.4B
– –
-76,721
Closed -$10.1M
MNKD icon
139
MannKind Corp
MNKD
$1.28B
– –
-1,852,563
Closed -$10.5M
MRVI icon
140
Maravai LifeSciences
MRVI
$997M
– –
-718,582
Closed -$2.34M
NHC icon
141
National Healthcare
NHC
$3.53B
– –
-28,577
Closed -$3.92M
NVAX icon
142
Novavax
NVAX
$1.23B
– –
-181,220
Closed -$1.22M
PTGX icon
143
Protagonist Therapeutics
PTGX
$8.75B
– –
-52,961
Closed -$4.63M
QURE icon
144
uniQure
QURE
$2.68B
– –
-62,820
Closed -$1.5M
REGN icon
145
Regeneron Pharmaceuticals
REGN
$68.8B
– –
-10,097
Closed -$7.79M
SEM
146
DELISTED
Select Medical
SEM
– –
-906,100
Closed -$13.5M
TEVA icon
147
Teva Pharmaceuticals
TEVA
$35.9B
– –
-660,177
Closed -$20.6M
UNH icon
148
UnitedHealth
UNH
$382B
– –
-60,862
Closed -$18.1M
RAPP
149
Rapport Therapeutics
RAPP
$1.95B
– –
-59,233
Closed -$1.8M
ZBIO
150
Zenas BioPharma
ZBIO
$1.92B
– –
-121,016
Closed -$4.39M
3 4 5
6
7

Similar funds

DCP
Distillate Capital Partners Chicago, Illinois $1.9B AUM 2.22% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $1.89B AUM 14.55% 1-Year Est. Return
OPCM
Osborne Partners Capital Management San Francisco, California $1.89B AUM 16.21% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
RCA
Resonant Capital Advisors Madison, Wisconsin $1.9B AUM 14.38% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $1.91B AUM 24.91% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TF
Trek Financial Scottsdale, Arizona $1.88B AUM 41.21% 1-Year Est. Return

Eversept Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Eversept Partners held 151 positions worth $1.9B, down 4.4% from $1.98B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Eversept Partners's Q1 2026 filing shows 44 new, 37 increased, 36 reduced and 31 closed positions. Its largest new stake was Welltower: 180,953 shares worth $35.8M. The largest sale was GSK, an estimated $48.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 90% a quarter earlier, followed by Real Estate and Financials.

  • Eversept Partners's largest Q1 2026 buy was Welltower: 180,953 shares worth $35.8M.
  • Eversept Partners added most to Brookdale Senior Living in Q1 2026, an estimated $44.7M increase.
  • Eversept Partners's biggest Q1 2026 reduction was GSK, cutting an estimated $48.5M.
  • Eversept Partners fully exited Danaher in Q1 2026, selling an estimated $42.6M.
  • Eversept Partners's ten largest holdings make up 48% of its $1.9B portfolio in Q1 2026.
  • Eversept Partners opened 44 new positions and closed 31 in Q1 2026.
  • Eversept Partners's portfolio value fell 4.4% quarter-over-quarter to $1.9B.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.